Bromocriptine in peripartum cardiomyopathy: A meta‐analysis with trial sequential analysis [PDF]
ESC Heart FailureBromocriptine has been proposed as a disease‐modifying therapy for peripartum cardiomyopathy (PPCM). The long‐term outcomes of bromocriptine use remain uncertain.
Umar G. Adamu +3 more
doaj +3 more sources
Repurposing of Bromocriptine for Cancer Therapy
Frontiers in Pharmacology, 2018 Bromocriptine is an ergot alkaloid and dopamine D2 receptor agonist used to treat Parkinson’s disease, acromegaly, hyperprolactinemia, and galactorrhea, and more recently diabetes mellitus.
Ean-Jeong Seo +3 more
doaj +2 more sources
Bromocriptine and insulin sensitivity in lean and obese subjects
Endocrine Connections, 2016 Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated.
L Bahler +6 more
doaj +2 more sources
Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine [PDF]
BMC Cardiovascular Disorders, 2021 Background Ergot-derived dopamine agonists are thought to induce fibrotic changes in cardiac valve leaflets. We sought to determine the incidence of heart valve disease in women treated with bromocriptine compared with age and sex matched controls from ...
Marianne F. Clausen +8 more
doaj +2 more sources
Bromocriptine treatment and outcomes in peripartum cardiomyopathy: the EORP PPCM registry. [PDF]
Eur Heart JBackground and Aims Peripartum cardiomyopathy (PPCM) remains a serious threat to maternal health around the world. While bromocriptine, in addition to standard treatment for heart failure, presents a promising pathophysiology-based disease-specific ...
van der Meer P +15 more
europepmc +2 more sources
Atherosclerosis enhances the efficacy of liposome-encapsulated bromocriptine in reducing the incidence of prolactinemia in pituitary tumors [PDF]
Journal of NanobiotechnologyIntranasal drug delivery via nanocarriers has long been a research focus for enhancing drug concentration in the brain. However, the strategy of exploiting blood–brain barrier (BBB) alterations in atherosclerotic mouse models to enhance nanoparticle ...
Zhe Zhang +12 more
doaj +2 more sources
Bromocriptine improves glucose tolerance in obese mice via central dopamine D2 receptor-independent mechanism. [PDF]
PLoS ONEBromocriptine, generally regarded as a dopamine D2 receptor agonist, has been used to treat patients with type 2 diabetes in the USA; however, its mechanisms of action including the receptors that mediate its anti-diabetic effects remain unclear ...
Hiroshi Tsuneki +11 more
doaj +2 more sources
Current Therapeutic Research, 2021 : Background: Although dopamine D2 receptor agonists, bromocriptine and cabergoline, are notable medications in the treatment of Parkinsonism, hyperprolactinemia, and hyperglycemia, there is an identified relationship between the utilization of D2-like ...
Mohammed Fouad Shalaby, MD +5 more
doaj +2 more sources
Journal of Immunology Research, 2015 Objective. Prolactin plays an important role on the disease flare of postpartum SLE patients. 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the ...
Qiu Qian +9 more
doaj +2 more sources
Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects [PDF]
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2012 Background: Bromocriptine-QR (a quick-release formulation of bromocriptine mesylate), a dopamine D2 receptor agonist, is a US Food and Drug Administrration–approved treatment for type 2 diabetes mellitus (T2DM).
Blonde, Lawrence +5 more
core +2 more sources